- Trials with a EudraCT protocol (596)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
596 result(s) found for: "prostate cancer" OR "breast cancer".
Displaying page 4 of 30.
| EudraCT Number: 2009-015981-73 | Sponsor Protocol Number: GERICO 09/0907 | Start Date*: 2009-12-08 | ||||||||||||||||
| Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) | ||||||||||||||||||
| Full Title: Phase II study evaluating the toxicity and activity of the combination lapatinib + capecitabine in elderly patients aged 70 and over with metastatic breast cancer over expressing HER2 | ||||||||||||||||||
| Medical condition: Locally advanced or metastatic breast cancer over expressing HER2 and ≥ 70 years old | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Ongoing) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-012809-19 | Sponsor Protocol Number: CLIN902 PCM203 | Start Date*: 2009-07-15 | |||||||||||
| Sponsor Name:STEBA BIOTECH SA | |||||||||||||
| Full Title: VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCER | |||||||||||||
| Medical condition: Localized prostate cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FR (Ongoing) NL (Completed) GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-000876-26 | Sponsor Protocol Number: CLIN801 PCM201 | Start Date*: 2008-05-02 | |||||||||||
| Sponsor Name:STEBA BIOTECH NV | |||||||||||||
| Full Title: "VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE" | |||||||||||||
| Medical condition: The Treatment of prostate cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FR (Ongoing) GB (Completed) NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-005213-39 | Sponsor Protocol Number: CJP4.2 | Start Date*: 2013-04-10 | |||||||||||
| Sponsor Name:CENTRE JEAN PERRIN | |||||||||||||
| Full Title: Phase II pilot study assessing efficacy of a Cisplatine – Métronomic Cyclophosphamide treatment in Patients with Stade IV Triple Negative breast Cancer Secondary Resistant to Anthracyclines and T... | |||||||||||||
| Medical condition: Triple negative metastatic breast cancer resistant secondary to anthracyclines and taxanes | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-018188-29 | Sponsor Protocol Number: Calendula study | Start Date*: 2010-08-06 | ||||||||||||||||
| Sponsor Name:Dept of Oncology | ||||||||||||||||||
| Full Title: Randomised blinded trial of Calendula Officinalis compared with aqueos cream for the prevention of acute skin toxicity in relation to radiotherapy for breast cancer | ||||||||||||||||||
| Medical condition: Patients operated for breast cancer who undergo postoperative adjuvant radiotherapy will be offered to participate in this randomized trial with the aim to reduce the risk of severe radiation skin ... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: SE (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2016-001852-23 | Sponsor Protocol Number: M14ABC | Start Date*: 2017-09-29 | |||||||||||
| Sponsor Name:NKI-AVL | |||||||||||||
| Full Title: A feasibility study of niraparib for advanced, BRCA1-like, HER2-negative breast cancer patients | |||||||||||||
| Medical condition: Breast cancer, advanced | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-001499-10 | Sponsor Protocol Number: CO34 | Start Date*: 2005-05-19 |
| Sponsor Name:Dr. José Ramón Mel Lorenzo | ||
| Full Title: 'Pilot trial of Pegilated Liposomal Doxorrubicin (Caelyx) in combination with Docetaxel (Taxotere) in advanced breast cancer patients' Estudio Piloto de Doxorrubicina Liposomal Pegilada (Caelyx) en... | ||
| Medical condition: Advanced Breast Cancer | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000801-21 | Sponsor Protocol Number: 20130218 | Start Date*: 2014-08-26 |
| Sponsor Name:Academic Medical Center | ||
| Full Title: Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: alternative versus standard stimulation protocols; the STIM-trial | ||
| Medical condition: Ovarian stimulation in women with breast cancer prior to chemotherapy | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-001161-27 | Sponsor Protocol Number: EUOG2014-001 | Start Date*: 2015-05-18 | |||||||||||
| Sponsor Name:European Uro- Oncology Group (EUOG) | |||||||||||||
| Full Title: An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Chemo-Naïve patients with Progressive Prostate C... | |||||||||||||
| Medical condition: Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-017788-40 | Sponsor Protocol Number: KEO09069EST | Start Date*: 2010-10-20 | |||||||||||
| Sponsor Name:CRLCC Alexis Vautrin | |||||||||||||
| Full Title: Etude de phase II randomisée multicentrique évaluant l'efficacité d’estramustine phosphate (Estracyt ®) chez des patientes présentant un cancer du sein métastatique HER2- / RH+ ayant déjà reçu un t... | |||||||||||||
| Medical condition: Metastases breast cancer in women already treated with aromatase inhibitors. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005230-18 | Sponsor Protocol Number: MA.32 | Start Date*: 2012-07-03 | |||||||||||
| Sponsor Name:NCIC Clinical Trials Group | |||||||||||||
| Full Title: A Phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer. | |||||||||||||
| Medical condition: Early Breast Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000276-38 | Sponsor Protocol Number: MIBIOTIMI | Start Date*: 2021-07-06 | |||||||||||
| Sponsor Name:Álvaro Ruibal Morell | |||||||||||||
| Full Title: Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response | |||||||||||||
| Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-001863-21 | Sponsor Protocol Number: BOOG2013-03 | Start Date*: 2013-09-04 | |||||||||||||||||||||
| Sponsor Name:BOOG Study Center | |||||||||||||||||||||||
| Full Title: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - the TRAIN-2 study | |||||||||||||||||||||||
| Medical condition: Breast cancer, HER2 positive, stage II or III | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2020-000245-13 | Sponsor Protocol Number: SOLTI-1907 | Start Date*: 2021-03-04 | |||||||||||
| Sponsor Name:SOLTI | |||||||||||||
| Full Title: A Phase II with 2 parallel cohorts clinical trial targeting estrogen receptor negative or PAM50 non-luminal disease with Atezolizumab in combination with Trastuzumab and Vinorelbine in HER2-positiv... | |||||||||||||
| Medical condition: Pre- and post-menopausal women with locally advanced or metastatic HER2-positive breast cancer who have progressed to trastuzumab/pertuzumab and T-DM1. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-001128-38 | Sponsor Protocol Number: pVAX/rhPSA -EP 2006 | Start Date*: 2008-09-30 |
| Sponsor Name:Uppsala University Hospital | ||
| Full Title: DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients with Relapsed Prostate Cancer. A Phase I/II Study | ||
| Medical condition: Patients with relapse of prostate cancer. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-003483-43 | Sponsor Protocol Number: PersonaLymPCa | Start Date*: 2020-01-08 | |||||||||||||||||||||
| Sponsor Name:Grupo de Investigación en Tumores Uro-oncológicos | |||||||||||||||||||||||
| Full Title: Phase II Safety and Efficacy of personalized lymphadenectomy or guided by Indocyanine Green (IGC) vs extended pelvic lymph node dissection in patients diagnosed with Prostate Cancer subsidiaries of... | |||||||||||||||||||||||
| Medical condition: We want to study the relationship between the extent of lymphadenectomy and surgical complications. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2016-002485-31 | Sponsor Protocol Number: OPIP | Start Date*: 2017-01-31 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Optimisation of [68Ga] PSMA-11 PET/CT Imaging Protocol for localizing primary prostate cancer prior to radical prostatectomy | ||
| Medical condition: Primary localised prostate cancer, in men who opt for active treatment in the form of a radical prostatectomy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-021962-31 | Sponsor Protocol Number: Protocolversion1-20100713 | Start Date*: 2011-10-06 | |||||||||||
| Sponsor Name:Bo Lennernäs | |||||||||||||
| Full Title: KEES- A single arm phase II trial of the peroral regimen KEES (Ketokonazole, Etoposide, Estramustine, Sendoxan) in patients with Castration Resistant Prostate Cancer (CRPC) | |||||||||||||
| Medical condition: Men with castration resistant prostate cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: SE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-023776-52 | Sponsor Protocol Number: Lisette-1 | Start Date*: 2011-01-19 | |||||||||||
| Sponsor Name: | |||||||||||||
| Full Title: Optimizing tamoxifen therapy through the induction of CYP3A4, CYP2C and CYP2D6 mediated metabolism | |||||||||||||
| Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-014662-26 | Sponsor Protocol Number: IRST 174.04 | Start Date*: 2009-11-06 | |||||||||||
| Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI | |||||||||||||
| Full Title: Phase II comparative study of Myocet plus Cyclophosphamide plus metformin versus Myocet plus Cyclophosphamide in first line treatment of HER2 negative metastatic breast cancer patients. | |||||||||||||
| Medical condition: HER2 negative metastatic breast cancer patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.